CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 150 target
Drug / intervention
Fentanyl Citrate Buccal Tablet +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04188418
NCT04188418Phase 3ActiveOn TrackUpdated 4mo ago

Efficacy and Safety of Rapid-Onset Opioids for Exertional Dyspnea in Cancer Patients

M.D. Anderson Cancer Center·interventional·Posted Dec 5, 2019·Updated Feb 19, 2026

In Brief

A Phase 3 clinical trial evaluating Fentanyl Citrate Buccal Tablet, Morphine, and 4 other interventions for Hematopoietic and Lymphoid Cell Neoplasm and Malignant Solid Neoplasm. Active but no longer recruiting, targeting 150 participants across 1 site.

Detailed Summary

This phase II trial studies fentanyl buccal tablet or morphine to see how well it works compared to a placebo in controlling shortness of breath during or after physical activity in cancer patients. Fentanyl sublingual tablet and morphine are opioids normally used to control pain that may also help to prevent or control shortness of breath during or after physical activity in cancer patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3Active
20202021202220232024202520262027
First PostedDec 5, 2019
Enrollment StartOct 23, 2020
Primary CompletionAug 31, 2027
TodayJul 1, 2026
Enrollment to primary: 6.9 yearsPosted 6.6 years agoPrimary completion in 1.2 years

Interventions

Fentanyl Citrate Buccal Tabletdrug

Given transmucosally

Morphinedrug

Given PO

Physical Performance Testingother

Complete shuttle walk test

Placebo Administrationother

Given PO

Quality-of-Life Assessmentother

Ancillary studies

Questionnaire Administrationother

Ancillary studies